News
Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...
Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...
Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback